Your browser doesn't support javascript.
loading
Oncohematological diseases in the Vale do Paraíba, State of São Paulo: demographic aspects, prevalences and incidences
Callera, Fernando; Brasil, Alvaro Azevedo Vital; Casali, Anna Raquel de Lima; Mulin, Carla Cecília; Rosa, Evandro Secchi; Barbosa, Maira de Assis; Vieira, Thais Domitila Freire.
  • Callera, Fernando; Grupo de Onco-hematologia do Vale do Paraíba. São José dos Campos. BR
  • Brasil, Alvaro Azevedo Vital; Grupo de Onco-hematologia do Vale do Paraíba. São José dos Campos. BR
  • Casali, Anna Raquel de Lima; Grupo de Onco-hematologia do Vale do Paraíba. São José dos Campos. BR
  • Mulin, Carla Cecília; Grupo de Onco-hematologia do Vale do Paraíba. São José dos Campos. BR
  • Rosa, Evandro Secchi; Grupo de Onco-hematologia do Vale do Paraíba. São José dos Campos. BR
  • Barbosa, Maira de Assis; Grupo de Onco-hematologia do Vale do Paraíba. São José dos Campos. BR
  • Vieira, Thais Domitila Freire; Grupo de Onco-hematologia do Vale do Paraíba. São José dos Campos. BR
Rev. bras. hematol. hemoter ; 33(2): 120-125, 2011. tab
Artículo en Inglés | LILACS | ID: lil-596301
ABSTRACT

BACKGROUND:

Based on the necessity of detailed information that supports effective strategies to improve cancer outcomes in the different regions of Brazil, the aims of this study were to report demographic aspects and to calculate the prevalence and incidence rates of oncohematological diseases in the region of Vale do Paraíba.

METHODS:

This is a multicentric prospective study carried out from October 2009 to March 2010. A total of 500 over 19-year-old patients were enrolled. Data such as type of healthcare insurance, gender, age, ethnic classification, place of residence, schooling, income, body mass index, new cases and the period between the first symptoms and a definite diagnosis were collected. The prevalence and incidence rates were calculated according to an estimated number of 1,319,800 inhabitants.

RESULTS:

The prevalence and incidence rates per 100,000 inhabitants in the period of six months were, respectively acute myeloid leukemia 1.5 and 0.7; acute lymphoblastic leukemia 0.5 and 0.1; chronic lymphocytic leukemia 2.4 and 0.4; chronic myeloid leukemia 6.2 and 0.8; Hodgkin's lymphoma 2.9 and 0.9; non-Hodgkin lymphoma 9.8 and 4.3; multiple myeloma 5.7 and 0.7; myelodysplastic syndromes 2.1 and 0.2 and myeloproliferative syndromes 5.1 and 0.3.

CONCLUSION:

Giving the paucity of data in this field of investigation, our data may be useful for comparisons with those of other regions of Brazil and will assist in the implementation of treatment programs of oncohematological diseases in this region.
Asunto(s)


Texto completo: Disponible Índice: LILACS (Américas) Asunto principal: Linfoma no Hodgkin / Enfermedad de Hodgkin / Neoplasias Hematológicas / Planificación en Salud Tipo de estudio: Ensayo Clínico Controlado / Estudio observacional / Factores de riesgo Límite: Anciano / Aged80 / Femenino / Humanos / Masculino Idioma: Inglés Revista: Rev. bras. hematol. hemoter Asunto de la revista: Hematología Año: 2011 Tipo del documento: Artículo País de afiliación: Brasil Institución/País de afiliación: Grupo de Onco-hematologia do Vale do Paraíba/BR

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Índice: LILACS (Américas) Asunto principal: Linfoma no Hodgkin / Enfermedad de Hodgkin / Neoplasias Hematológicas / Planificación en Salud Tipo de estudio: Ensayo Clínico Controlado / Estudio observacional / Factores de riesgo Límite: Anciano / Aged80 / Femenino / Humanos / Masculino Idioma: Inglés Revista: Rev. bras. hematol. hemoter Asunto de la revista: Hematología Año: 2011 Tipo del documento: Artículo País de afiliación: Brasil Institución/País de afiliación: Grupo de Onco-hematologia do Vale do Paraíba/BR